Background: Adverse events (e.g., pyrexia) may affect treatment patterns and adherence. This study explored pyrexia risk tolerance among melanoma patients when treatment benefit is unknown versus known. Materials & methods: US respondents with stage III (n = 100) or stage III unresectable/stage IV melanoma (n = 125) chose between hypothetical melanoma treatments, defined by reoccurrence/progression-free survival and pyrexia risk, one resembling standard-of-care and one resembling dabrafenib + trametinib. Respondents chose first when efficacy was unknown and then when efficacy was known; pyrexia risk was varied systematically to define maximum acceptable risk. Results: Maximum acceptable risk of pyrexia was statistically significantly higher when efficacy was known versus unknown in stage III patients (85 vs 34%) and stage III unresectable/stage IV patients (66 vs 57%). Conclusion: Patients accepted higher levels of pyrexia risk when they understood treatment benefit.
Risk tolerance in adjuvant and metastatic melanoma settings
A patient perspective study using the threshold technique
Mansfield, C., Myers, K., Klein, K., Patel, J., Nakasato, A., Ling, Y-L., & Tarhini, A. A. (2021). Risk tolerance in adjuvant and metastatic melanoma settings: A patient perspective study using the threshold technique. Future Oncology, 17(17), 2151-2167. https://doi.org/10.2217/fon-2020-1193